-
How many of your patients rely on vasectomy for contraception? About 500,000 vasectomies are performed each year in the United States; about one out of six U.S. men over age 35 has been vasectomized, with prevalence increasing with education and income.
-
Results from a Phase III study in men ages 16 to 26 indicate that the human papillomavirus (HPV) vaccine Gardasil (Merck & Co.) prevented 90% of external genital lesions caused by types 6, 11, 16, and 18 of HPV.
-
Good news: About 75% of respondents to the 2008 Contraceptive Technology Update Salary Survey say they received increases in their paychecks in the last year. Bad news: The majority (57%) saw only a 1%-3% increase.
-
Results from a just-published study indicate that teens who are treated for pelvic inflammatory disease (PID) are at risk for subsequent sexually transmitted infections (STIs) and/or PID for 48 months.1 What can clinicians do to stem subsequent infection?
-
When it comes to current methods of delivery of hormonal contraception, women now can choose among pill, patch, ring, implant, and intrauterine forms of birth control.
-
With the inauguration of President Barack Obama and with expanded Democratic majorities in both chambers of Congress, reproductive health supporters in the administration, in Congress, and outside the government are entering the new year with renewed optimism.
-
A large prospective cohort study of perineal talc use demonstrated no increased risk of ovarian cancer overall or within any histological subtype. In addition, no association with talc application method was observed.
-
According to this pharmacokinetic study, the cyclic use of 20 mcg ethinyl estradiol oral contraceptives is problematic for obese women. Ovarian activity was better suppressed with continuous use (omitting the hormone-free interval) of the same dose oral contraceptive or increasing to a higher dose 30 mcg ethinyl estradiol oral contraceptive
-
Polycystic ovarian syndrome patients with normospermic partners undergoing ovulation induction with letrozole had a higher live birth rate and no increase in adverse outcomes than women who received clomiphene citrate.
-
Circle your calendar for the upcoming annual Contraceptive Technology Conferences. The San Francisco conference is scheduled for March 12-15, with the Washington, DC, conference set for March 26-29.